Anamorelin combined with chemoimmunotherapy reverses cachexia in NSCLC, improving OS despite no PFS gain.
Background
Patients with advanced non-small cell lung cancer (NSCLC) often suffer from cancer cachexia, a debilitating syndrome characterized by involuntary weight loss and metabolic dysfunction, which significantly worsens prognosis. Current standard-of-care treatments for NSCLC, including chemoimmunotherapy, do not effectively address cachexia, leaving a critical gap in patient management. Anamorelin, a ghrelin receptor agonist, is approved in Japan specifically for cancer cachexia, offering a potential mechanism to counteract this wasting syndrome by stimulating appetite and growth hormone release, thereby improving body composition and quality of life.
Study Design
This prospective multicenter observational study, SPIRAL-ANA, evaluated Anamorelin's impact on efficacy and safety when combined with chemoimmunotherapy in patients with NSCLC and cancer cachexia. 123 patients were enrolled from 29 institutions in Japan, with 114 included in the full analysis set. The primary endpoint was progression-free survival (PFS), compared against a predefined 5-month threshold from a historical cohort. Secondary endpoints included overall survival (OS), objective response rate (ORR), and the rate of transition from cachectic to non-cachectic state, assessed at week 12. Safety was monitored for adverse events.
Results
The study enrolled 123 patients, with 114 in the full analysis set. The objective response rate (ORR) was 57.9% (95% CI: 48.7%-66.6%). Median PFS was 6.2 months (95% CI: 4.6-7.7), which did not exceed the predefined 5-month threshold, indicating no significant prolongation of PFS. Median overall survival (OS) was 18.5 months (95% CI: 13.1-28.6).
Key Findings
- Anamorelin combined with chemoimmunotherapy did not prolong median PFS beyond the 5-month predefined threshold (median PFS: 6.2 months).
- Median overall survival (OS) was 18.5 months (95% CI: 13.1-28.6).
- At
week 12, 61 of 85 patients (71.8%) transitioned from cancer cachexia to a non-cachectic state. Patients achieving cachexia reversal at
week 12had significantly longer OS (19.9 vs. 7.1 months; HR: 2.19; p=0.0098) compared to those remaining cachectic.- Grade ≥ 3 hyperglycemia was observed in six patients (5.1%), with no new safety signals identified.
Why It Matters
This study highlights a critical distinction: while Anamorelin didn't directly extend progression-free survival, its profound impact on cachexia reversal translated into a significant overall survival benefit. For peptide users and clinicians, this suggests that targeting cancer cachexia with Anamorelin could be a crucial adjunctive strategy in NSCLC management, even if it doesn't directly enhance tumor response. Improving nutritional status and body composition can independently extend life, offering a new dimension to cancer care beyond direct tumoricidal effects. This finding supports integrating cachexia-specific treatments into comprehensive oncology protocols, moving beyond a sole focus on tumor shrinkage. The protocol for Anamorelin administration in this context appears safe and effective for cachexia reversal, suggesting its potential for broader clinical adoption where approved.
anamorelin
nsclc
cancer-cachexia
ghrelin-receptor-agonist
chemoimmunotherapy
overall-survival